Researchers also demonstrated that AKT and RNF167-mediated CASTOR1 degradation activates mTORC1 and promotes breast cancer progression.
These patient-derived novel cell lines have the potential to identify therapeutic targets in ovarian cancer.
Using tissue from different high-grade serous epithelial ovarian cancer (EOC) patients, four unique antibody secreting plasma cell lines were isolated.
Immunotherapy Advances for Epithelial Ovarian Cancer.
This approach has shown the potential of both surgical and chemical approaches to “activate” SSCs present in humans to promote regeneration of bone in the absence of biomaterial implants or other osteogenic tissue implants. Applications. • Osteoporosis prevention. • Traumatic bone injuries. • Congenital bone abnormalities.
This technology employs a spin-lock MRI method to isolate chemical exchange–specific relaxation, providing a linear, quantitative measure of proteoglycan content within tissues.
It integrates traditional risk factors—blood pressure, lipid profiles, smoking status, diabetes—with female-specific variables such as adverse pregnancy outcomes, menopausal status, and circulating sex hormone levels.
- Enhanced predictive accuracy for midlife women through integration of female‐specific factors (adverse pregnancy outcomes, menopause status, sex hormone levels) alongside traditional CVD risk factors.
By incorporating reproductive health data alongside conventional metrics, the model captures risk signals unique to midlife women.
University of Pittsburgh researchers have identified a novel extracellular protein domain in hepatocellular carcinoma (HCC) and developed a monoclonal antibody (mAb) to recognize this target.
Established in a controlled laboratory environment with rigorous consent protocols, it has been meticulously developed to serve as an effective in vitro platform for studying breast cancer biology and therapeutic responses.
This tool has gained recognition in prominent scientific forums and is being shared with the broader research community through established agreements, enhancing collaborative efforts to advance treatment strategies for breast cancer.
- Addresses a critical gap in available breast cancer research models, particularly for ER-negative ILC.
University of Pittsburgh scientists have developed a novel approach to human immunodeficiency virus (HIV) and sexually transmitted infection (STI) prevention.
Researchers have developed a prodrug-based amphiphilic polymer (PASA) for the codelivery of small molecule drugs and chemotherapeutic agents that targets cancer stem cells in solid tumors.
• Pregnancy and other temporary insulin use.
Recognizing substance use during pregnancy can lead to harm reduction interventions, improving pregnancy outcomes and child health.
SBIRT and Obstetrics has been specifically tailored to healthcare professionals (HCPs) working in primary care settings to arm them with the ability to screen for substance use and provide education to address this issue in pregnancy.
A University of Pittsburgh research group, Pharmacy Evaluation and Research Unit (PERU), has developed a novel educational tool, SBIRT (Screening, Brief Intervention, Referral to Treatment) and Obstetrics.
Investigation of the presence of antibodies against Zika prior and during pregnancy is very important to implement infection prevention measures and to determine the viral infection of the mother.
Disturbance in the maintenance of normal mineral-ion and vitamin D balance results in kidney stones and osteoporosis.
No pharmaceutical therapy is available for the treatment of PTHR hyperactivity, and the only bone-building agents designed to treat osteoporosis have limited efficacy, short plasma lifetimes, and require restricted usage due to the risk of developing osteosarcoma.
· Developing drugs to treat hyperparathyroidism and its related pathologies, such as osteoporosis.
University of Pittsburgh researchers have developed a novel therapy for chondrocyte aging and, ultimately, osteoarthritis (OA).
In recent years, HPV vaccines and pap smears have reduced the rates of genital HPV+ cancers.
• Other HPV+ oropharyngeal cancers.
This liquid biopsy could be assessed for biomarkers of HPV+ cancers including analysis of cfDNA using NGS techniques.
